Ridgeback Capital Management

Ridgeback Capital Management is an active New York-based investment firm specializing in life science sectors including biotechnology and healthcare. Founded by Wayne Holman MD in 2006, it manages over $500 million AUM and has made at least 30 investments with 12 exits. The fund invests in both private and public companies developing innovative therapeutics across multiple modalities and indications. Recent notable investments include Hinge Bio (autoimmune disease therapies), Pyxis Oncology (oncology), Quell Therapeutics (cell therapy for immune disorders), Arbor Biotechnologies (gene editing), Freenome (cancer diagnostics) among others. The team has deep sector expertise with Wayne Holman previously at Sigma Capital. It does not develop drugs or technologies itself but backs leading-edge biotech innovators.